Policy Notices

• Updates to the Non-Discrimination Legal Requirements for NIH Recipients
  (NOT-OD-21-181)
  National Institutes of Health
  

General Notices

• Notice of Pre-Application Webinar for the "Translational and Basic Science Research in Early Lesions (TBEL)" Program: RFA-CA-21-054 and RFA-CA-21-055
  (NOT-CA-21-115)
  National Cancer Institute
  

• The NIH Office of Disease Prevention (ODP) Announces the Pathways to Prevention Workshop: Improving Rural Health Through Telehealth-Guided Provider-to-Provider Communication
  (NOT-OD-21-184)
  Office of Disease Prevention
  

• Update for PAR-20-280 "Cooperative Research Agreements Related to the World Trade Center Health Program (U01)"
  (NOT-OH-21-015)
  National Institute for Occupational Safety and Health
  

• Request for Information (RFI): Unhealthy Alcohol Use in Active Duty Military
  (NOT-AA-21-042)
  National Institute on Alcohol Abuse and Alcoholism
  

• Request for Information (RFI): Research Opportunities to End Hunger, Food and Nutrition Insecurity.
  (NOT-OD-21-183)
  Office of the Director, NIH
  Office of Research on Women's Health
  

Notice of Changes to Funding Opportunities

• Notice of Early Expiration of NOT-AG-21-015 "Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19)"
  (NOT-AG-21-061)
  National Institute on Aging
  

• Notice of Correction to the Key Date Section in PAR-21-320, "NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)"
  (NOT-DA-21-080)
  National Institute on Drug Abuse
  

• Notice of NHLBI Participation in PAR-21-154, "Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Required)"
  (NOT-HL-21-031)
  National Heart, Lung, and Blood Institute
  

• Notice of NHLBI Participation in PAR-21-155, "Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed)"
  (NOT-HL-21-032)
  National Heart, Lung, and Blood Institute
  

• Notice of Change to Key Dates for RFA-NS-21-010 "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)"
  (NOT-NS-22-021)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Correction to Application and Submission Information for NOT-NS-21-068 "HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Advance the Study of Chronic Overlapping
  (NOT-NS-22-024)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Change to Application Types Allowed for RFA-NS-21-010 "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)"
  (NOT-NS-22-025)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Change to PAR-21-277 "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Institutionally-Focused Research Education Award to Promote Diversity (UE5 - Clinical Trial Not Allowed)"
  (NOT-OD-21-185)
  National Institutes of Health
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required)
  (NOT-AT-21-017)
  National Center for Complementary and Integrative Health
  National Heart, Lung, and Blood Institute
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute on Minority Health and Health Disparities
  National Institute of Nursing Research
  Office of Behavioral and Social Sciences Research
  Office of Research on Women's Health
  

• Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional)
  (NOT-AT-21-018)
  National Center for Complementary and Integrative Health
  National Heart, Lung, and Blood Institute
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute on Minority Health and Health Disparities
  National Institute of Nursing Research
  Office of Behavioral and Social Sciences Research
  Office of Research on Women's Health
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Coordinating Center for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (U24 Clinical Trial Required)
  (NOT-CA-21-112)
  National Cancer Institute
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Research Bases for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required)
  (NOT-CA-21-113)
  National Cancer Institute
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required)
  (NOT-CA-21-114)
  National Cancer Institute
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Adolescent Medicine Trials Network for HIV/AIDS Intervention (ATN) Scientific Leadership Center (UM2 Clinical Trial Required), and Operations and Collaborations Center (UM1 Clinical Trial)
  (NOT-HD-21-043)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• Notice of Intent to Publish a Funding Opportunity Announcement for NIH Blueprint for Neuroscience Research Short Courses in Neurotherapeutics Development (R25 Clinical Trial Not Allowed)
  (NOT-NS-22-023)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Evaluation of sex differences on HIV-associated comorbidities in the context of stimulant use
  (NOT-DA-21-020)
  National Institute on Drug Abuse
  

Funding Opportunities

• Making Health Care Safer in Ambulatory Care Settings and Long-term Care Facilities (R18)
  (PA-21-267)
  Agency for Healthcare Research and Quality
  Application Receipt Date(s): Standard dates apply. The first standard due date for the FOA is January 25, 2022. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Administrative Supplements to Promote Diversity in Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed)
  (PA-21-345)
  Office of the Director, NIH
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Center for Environmental Health
  National Cancer Institute
  National Center for Injury Prevention and Control
  National Eye Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Institute of General Medical Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  National Institute for Occupational Safety and Health
  National Library of Medicine
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  Application Receipt Date(s): Applications are accepted on a rolling basis at any time starting 30 days after the Open Date until the expiration date, unless otherwise noted in Institute specific language. Please consult with Scientific contacts listed in Section VII. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Emerging Global Leader Award (K43 Independent Clinical Trial Required)
  (PAR-21-251)
  John E. Fogarty International Center
  National Cancer Institute
  National Human Genome Research Institute
  National Institute on Aging
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  Office of Research on Women's Health
  Application Receipt Date(s): November 3, 2021, November 3, 2022, and November 3, 2023 by 5:00 PM local time of the applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  
  

• Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)
  (PAR-21-252)
  John E. Fogarty International Center
  National Cancer Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute of Dental and Craniofacial Research
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  Office of Research on Women's Health
  Application Receipt Date(s): November 3, 2021, November 3, 2022, and November 3, 2023 by 5:00 PM local time of the applicant organization. Alltypes of non-AIDS applicationsallowed for this funding opportunity announcement are due on these dates.
  
  

• NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Clinical Trial Required)
  (PAR-21-299)
  National Cancer Institute
  Application Receipt Date(s): Standard dates apply. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applications are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Independent Clinical Trial Not Allowed)
  (PAR-21-300)
  National Cancer Institute
  Application Receipt Date(s): Standard dates apply. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applications are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• NCI Transition Career Development Award to Promote Diversity (K22 Independent Clinical Trial Not Allowed)
  (PAR-21-301)
  National Cancer Institute
  Application Receipt Date(s): Standard dates apply. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applications are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required)
  (PAR-21-302)
  National Cancer Institute
  Application Receipt Date(s): Standard dates apply. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applications are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required)
  (PAR-21-327)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  
  

• Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Not Allowed)
  (PAR-21-328)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
  
  

• Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
  (PAR-21-330)
  National Cancer Institute
  Application Receipt Date(s): October 11, 2024
  
  

• AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)
  (PAS-21-270)
  National Institute on Drug Abuse
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products (R01 - Clinical Trial Optional)
  (RFA-DA-22-028)
  National Institute on Drug Abuse
  Application Receipt Date(s): February 09, 2022
  
  

• Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products (R21 - Clinical Trial Optional)
  (RFA-DA-22-039)
  National Institute on Drug Abuse
  Application Receipt Date(s): February 09, 2022
  
  

• High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
  (RFA-DA-22-040)
  National Institute on Drug Abuse
  Application Receipt Date(s): February 15, 2024
  
  

• An Intergenerational Precision Medicine Research Program for the Study of Factor VIII Immunogenicity in Severe Hemophilia A: Hemophilia A Analytical Cohort Research Program (UG3/UH3 Clinical Trial Not Allowed)
  (RFA-HL-22-004)
  National Heart, Lung, and Blood Institute
  Application Receipt Date(s): October 19, 2021
  
  

• Detecting Cognitive Impairment, Including Dementia, in Primary Care and Other Everyday Clinical Settings for the General Public and Health Equity, Pragmatic Clinical Trials (U01 Clinical Trial Required)
  (RFA-NS-22-009)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): November 10, 2021
  
  

• Small Vessel VCID Biomarkers Validation Consortium Coordinating Center (U24 Clinical Trial Not Allowed)
  (RFA-NS-22-017)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): November 12, 2021
  
  

• The Human BioMolecular Atlas Program (HuBMAP) Demonstration Project (U01 Clinical Trial Not Allowed)
  (RFA-RM-21-027)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): November 19, 2021